NONOF - Novo Nordisk comes under Senate probe over pricing for weight loss drugs
2024-04-24 15:42:21 ET
More on Novo Nordisk
- Novo Nordisk Remains The Better Buy After A Moderate Pullback
- Novo Nordisk: The Moat Won't Last Forever
- Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront
- 3.6M Medicare patients could qualify for Wegovy coverage: report
- TikTok to restrict weight loss drug promotion (updated)